NGM NGM Biopharmaceuticals

NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

NGM Bio to Host Conference Call to Discuss Preliminary Topline Results, Including Histology Data, from 24-Week Phase 2 Study of Aldafermin in Patients with NASH

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) will host a conference call and live webcast on Monday, February 24, 2020 at 8:30 a.m. ET (5:30 a.m. PT) to discuss preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive Phase 2 study of aldafermin (formerly NGM282) in patients with non-alcoholic steatohepatitis, or NASH, with stage 2 or 3 liver fibrosis. Conference call and webcast details are as follows:

Live Conference Call

Domestic Callers: (844) 873-0551

International Callers: (602) 563-8472

Passcode: 2466937   

Live and Archived Webcast                                   

For the live or archived webcast, please visit the “Investors & Media” section of NGM’s website at . The webcast will be archived for 30 days.

Archived Conference Call  

Domestic Callers: (855) 859-2056

International Callers: (404) 537-3406

Passcode: 2466937



The archived conference call will be available for 30 days.

About NGM Biopharmaceuticals, Inc.

NGM is a biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company leverages its biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable it to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. NGM aspires to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit  for more information.

Investor Contact:



Sylvia Wheeler and Alex Santos





Media Contact:



Liz Melone

EN
23/02/2020

Underlying

NGMNGM Biopharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NGM Biopharmaceuticals

 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Announces Closing of Tender Offer

NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain oth...

April 5, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ong...

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have be...

March 19, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter...

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravida...

March 11, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger wit...

NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2...

February 26, 2024 1 EN
 PRESS RELEASE
Free
NGM NGM Biopharmace...

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference

NGM Bio to Participate in the Cowen 44th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available under the Investors and M...

February 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch